The natural vitamin D hormone, 1 alpha,25-dihydroxyvitamin D-3 (1 alph
a,25-(OH)(2)D-3), not only regulates serum and bone calcium homeostasi
s but is probably also a paracrine factor in several cells and tissues
including skin, immune system, placenta and brain, where it stimulate
s cell differentiation and inhibits cell proliferation. Several struct
ural analogs of 1 alpha,25-(OH)(2)D-3 not only have superagonist activ
ity but also display a selective action profile: indeed they maintain
or have increased activity on cell differentiation/proliferation but a
lso have substantially decreased calcemic activity when compared to 1
alpha,25-(OH)(2)D-3. This decreased calcemic activity is partially due
to mere pharmacological reasons: because of low binding affinity for
the plasma vitamin D-binding protein, a more rapid extracellular metab
olism and increased cellular uptake is possible when compared to 1 alp
ha,25-(OH)(2)D-3. Their short extracellular half-life combined with co
mparable or enhanced transactivation potency together with analog- and
cell-type-specific intracellular metabolism can probably explain why
some analogs have a unique combination of superagonist activity and sp
ecific action profile with favorable dissociation of differentiation v
ersus calcemic potency.